Anupam Rasayan FY26 results: revenue jumps to ₹2,384 cr

Key takeaway from the FY26 print

Anupam Rasayan India Ltd reported its earnings for the fourth quarter and full year ended March 31, 2026, showing strong year-on-year growth in revenue for both periods. For Q4, the topline expanded compared with the same quarter last year, but net profit and earnings per share were marginally lower. For the full year, the company reported a sharp jump in sales, revenue, and net profit versus the previous year. The update adds to a series of quarterly disclosures and operational commentary the company has shared through FY26.

Q4 FY26: revenue rose, net profit eased

For the fourth quarter ended March 31, 2026, the company reported sales of ₹635.78 crore, up from ₹500.16 crore a year earlier. Revenue for the quarter came in at ₹639.15 crore, compared with ₹505.70 crore in the year-ago quarter. Net income for Q4 FY26 was ₹42.65 crore, slightly lower than ₹44.57 crore reported in Q4 of the prior year. Basic earnings per share from continuing operations was ₹3.75 versus ₹4.06 a year ago, and diluted EPS was also ₹3.75 versus ₹4.06.

Full-year FY26: strong jump in sales, revenue, and profit

For the full year ended March 31, 2026, Anupam Rasayan reported sales of ₹2,365.46 crore, up from ₹1,436.97 crore in the previous year. Revenue for FY26 was ₹2,383.63 crore, compared with ₹1,448.45 crore a year earlier. Net income increased to ₹170.12 crore, up from ₹93.35 crore in the prior year. Basic EPS from continuing operations rose to ₹15.09 from ₹8.50, and diluted EPS was ₹15.09 versus ₹8.50.

Snapshot table: Q4 and FY26 reported numbers

FY26 quarterly trail: Q2 and Q3 updates referenced

Beyond the Q4 and FY26 results, the shared material also referenced earlier quarterly performance in FY26. Anupam Rasayan reported a 12% increase in net profit to ₹61 crore for Q3 FY26, driven by a 31.35% rise in total revenue to ₹512.44 crore. For Q2 FY26, the company reported total revenue of ₹739.20 crore compared with ₹295.90 crore in Q2 FY25, a year-on-year increase of 149%. Q2 FY26 EBITDA (including other income) was ₹143.60 crore versus ₹82.40 crore in Q2 FY25, translating to a 19% EBITDA margin for the quarter as stated. Profit after tax for Q2 FY26 was reported at ₹57.20 crore, up from ₹30.60 crore in Q2 FY25.

Management commentary and subsidiary performance

In the Q2 FY26 update, Managing Director Anand Desai said the quarter was among the company’s best, citing consolidated revenue from operations of ₹739 crore and 149% year-on-year growth, along with 51% sequential growth. The same commentary stated that for H1 FY26, consolidated revenue stood at ₹1,229 crore, up 122% year-on-year. It also noted that within six months of the financial year, the company had surpassed the total revenue of FY25. The management note added that subsidiary Tanfac Industries reported H1 FY26 revenue of ₹345 crore, marking 67% year-on-year growth.

Business mix indicators shared in the FY26 narrative

The provided material also included segment-level indicators for Q1 FY26. It said life sciences-related specialty chemicals contributed 88% of revenue in Q1 FY26. The pharma segment accounted for 24% of revenue in Q1 FY26 versus 15% in the prior year, with the note attributing the increase to ramp-up of new molecules launched in the last 18 to 24 months. Performance materials contributed 12% of total revenue in Q1 FY26 versus 10% in Q1 FY25, linked to commercialization under recently signed contracts. The same narrative highlighted the USA and Japan markets as showing “encouraging trends” for the company.

Capital actions and debt position mentioned

A separate operational update stated that the company received ₹277.50 crore from a preferential issue in July 2025. Out of this, ₹175 crore was used to repay term debt, and the company described itself as long-term net debt free after the repayment. Such disclosures matter for investors tracking leverage and interest-cost sensitivity, especially for companies with capacity expansion and multi-year contract pipelines. These details were shared as part of the company’s FY26 commentary and are distinct from the audited Q4 and full-year result line items.

Stock, acquisition headline, and disclosures timeline

The material also noted that Anupam Rasayan’s stock surged following its $150 million acquisition of US-based Jayhawk Fine Chemicals, indicating a market reaction to the deal announcement. Separately, it said an audio recording of the earnings call for the quarter and nine months ended December 31, 2025 was posted on the company website on February 14, 2026. The current price of Anupam Rasayan India Ltd was listed as ₹1,371.10 in the provided text. An event line also referenced “Q4 2026 Earnings Release” dated 06/08/2026.

What the FY26 numbers tell investors

The FY26 statement combines two messages that investors typically separate: a strong full-year growth profile and a softer year-on-year comparison in Q4 profitability and EPS. FY26 revenue increased sharply to ₹2,383.63 crore and net income rose to ₹170.12 crore, reflecting a materially higher earnings base than FY25. But in Q4, while revenue moved up to ₹639.15 crore, net income dipped to ₹42.65 crore and EPS fell to ₹3.75 from ₹4.06. The mix and operational notes shared for FY26 also emphasize ramp-up in pharma and polymer-linked products, recovery trends in agrochemicals, and higher export contribution in some quarters.

Conclusion

Anupam Rasayan’s FY26 results showed a significant year-on-year rise in revenue, sales, and net profit, while Q4 profitability and EPS were modestly lower than the year-ago quarter. Management commentary during the year pointed to stronger traction in pharma and performance materials, along with a stated improvement in the company’s debt profile after the July 2025 preferential issue and term-debt repayment. Investors are likely to track subsequent disclosures around contracts, segment execution, and scheduled earnings-related updates referenced in the timeline provided.